Researchers have for the first time documented a case of an individual contracting HIV, a multi-drug resistant strain, while apparently adhering well to the daily regimen of Truvada as pre-exposure prophylaxis (PrEP). The scientists concluded that it is indeed...
A long-acting injectable formulation of ViiV’s cabotegravir and Janssen’s Edurant (rilpivirine), dosed every four or eight weeks, is safe and generally well tolerated and suppresses HIV as well as a daily oral regimen in an ongoing trial. The companies intend to...
The U.S. Food and Drug Administration has approved the single-tablet HIV treatment regimen Odefsey, which includes a new, safer version of tenofovir. The tablet is an updated version of Complera, swapping tenofovir alafenamide, or TAF, for tenofovir disoproxil...
